Efficacy of satralizumab therapy in the treatment of NMOSD
DOI:
https://doi.org/10.56782/pps.166Keywords:
NMOSD, satralizumab, AQP4Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affecting the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2022. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.
Downloads
References
Traboulsee, A., et al., Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol., 2020, 19(5), 402-412. doi:10.1016/s1474-4422(20)30078-8. DOI: https://doi.org/10.1016/S1474-4422(20)30078-8
Shumway CL, Patel BC, De Jesus O. Neuromyelitis Optica (NMO, Devics Disease) [Updated 2023 Feb 12]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 https://www.ncbi.nlm.nih.gov/books/NBK572108/ (data dostepu: 2023.08.14).
Zapalenie rdzenia i nerwów wzrokowych (zespół Devica, neuromyelitis optica). 2023; https://podyplomie.pl/wiedza/neurologia/188,zapalenie-rdzenia-i-nerwow-wzrokowych-zespol-devica-neuromyelitis-optica (data dostępu: 2023.08.14).
Seok, J.M., et al., Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using a deep learning model. Sci. Rep. 2023, 13(1), 11625. doi:10.1038/s41598-023-38271-x. DOI: https://doi.org/10.1038/s41598-023-38271-x
Gospodarczyk-Szot, K., et al., Zapalenie nerwów wzrokowych i rdzenia Devica (NMO) oraz choroby ze spektrum NMO. Polski Przegląd Neurologiczny 2016, 12(4), 196-205. doi:10.5603/ppn50689.
Pandit, L., et al., Demographic and clinical features of neuromyelitis optica: A review. Mult. Scler. 2015, 21(7), 845-53. doi:10.1177/1352458515572406. DOI: https://doi.org/10.1177/1352458515572406
Iyer, A., et al., A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity 2014. 47(3), 154-61. doi:10.3109/08916934.2014.883501. DOI: https://doi.org/10.3109/08916934.2014.883501
Graber, D.J., et al., Neuromyelitis optica pathogenesis and aquaporin 4. J. Neuroinflammation, 2008, 5, 1-21. doi:10.1186/1742-2094-5-22. DOI: https://doi.org/10.1186/1742-2094-5-22
Jasiak-Zatońska, M., et al., Relationship between blood-brain permeability and antibodies against aquaporins in neuromyelitis optica spectrum disorders and multiple sclerosis patients. Neurol. Neurochir. Pol., 2022, 56(4), 308-317. doi:10.5603/PJNNS.a2022.0007. DOI: https://doi.org/10.5603/PJNNS.a2022.0007
Fujihara, K., et al., Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol. Neuroinflamm., 2020, 7(5), doi:10.1212/nxi.0000000000000841. DOI: https://doi.org/10.1212/NXI.0000000000000841
Jasiak-Zatońska, M., et al., Different blood-brain-barrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol. Neurochir. Pol., 2022, 56(3), 246-255. doi:10.5603/PJNNS.a2022.0013. DOI: https://doi.org/10.5603/PJNNS.a2022.0013
Jak rozpoznawać i leczyć NMOSD. https://www.mp.pl/neurologia/aktualnosci/308860,jak-rozpoznawac-i-leczyc-nmosd (data dostępu: 2023-08-14).
Informacja prasowa FDA dotycząca zatwierdzenia leku Soliris (eculizumab). https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central (data dostępu: 2023-08-14).
Dubois, E.A.; A.F. Cohen, A.F. Eculizumab. B.r J.Clin. Pharmacol., 2009, 68(3), 318-9. doi:10.1111/j.1365-2125.2009.03491.x. DOI: https://doi.org/10.1111/j.1365-2125.2009.03491.x
Charakterystyka produktu leczniczego Soliris (EMA). https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_pl.pdf (data dostępu: 2023-08-14).
Raport EMA dotyczący leku Uplizna. https://www.ema.europa.eu/en/documents/overview/uplizna-epar-medicine-overview_pl.pdf (data dostępu: 2023-08-14).
Nie, T. and H.A. Blair, Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder. CNS Drugs, 2022, 36(10), 1133-1141. doi:10.1007/s40263-022-00949-7 DOI: https://doi.org/10.1007/s40263-022-00949-7
Satralizumab - Program lekowy B.138.FM. https://www.gov.pl/attachment/0322e6fd-861b-4365-84cc-c60c964dc465 (data dostępu: 2023-08-14).
Fung, S. and M. Shirley, Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder. CNS Drugs, 2023, 37(4), 363-370. doi:10.1007/s40263-023-00995-9. DOI: https://doi.org/10.1007/s40263-023-00995-9
Duchow, A.; J. Bellmann-Strobl, J. Satralizumab in the treatment of neuromyelitis optica spectrum disorder. Neurodegener. Dis. Manag., 2021, 11(1), 49-59. doi:10.2217/nmt-2020-0046. DOI: https://doi.org/10.2217/nmt-2020-0046
Raport EMA dotyczący leku RoActemra (tocilizumab). https://www.ema.europa.eu/en/documents/overview/roactemra-epar-medicines-overview_pl.pdf (data dostępu: 2023-08-14).
Zhang, C., et al., Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol., 2020, 19(5), 391-401. doi:10.1016/s1474-4422(20)30070-3. DOI: https://doi.org/10.1016/S1474-4422(20)30070-3
Charakterystyka Produktu Leczniczego Enspryng (EMA). https://www.ema.europa.eu/en/documents/product-information/enspryng-epar-product-information_pl.pdf. (data dostępu: 2023-08-14).
Enspryng (satralizumab) jako technologia lekowa o wysokim poziomie innowacyjności, Agencja Oceny Technologii Medycznych. https://bipold.aotm.gov.pl/assets/files/wykaz_tli/RAPORTY/2022/Enspryng_8_2022_BIP.pdf. (data dostępu: 2023-08-14).
Satralizumab - nowy lek refundowany w Polsce i długoterminowe dane potwierdzające jego skuteczność. https://www.kierunekfarmacja.pl/artykul,97085,najnowsze-dane-dlugoterminowe-potwierdzaja-skutecznosc-satralizumabu-w-leczeniu-nmosd.html (data dostępu: 2023-08-14).
Kleiter, I., et al., Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol.: Neuroimmunol. Neuroinflammation, 2023, 10(1), 200071. doi:10.1212/nxi.0000000000200071. DOI: https://doi.org/10.1212/NXI.0000000000200071
Wingerchuk, D.M., et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85(2), 177-89. doi:10.1212/wnl.0000000000001729. DOI: https://doi.org/10.1212/WNL.0000000000001729
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patrya
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
